Gelteq shares surge 50.64% after-hours on positive preclinical results showing 22% higher CBD bioavailability.

Gelteq Ltd (NASDAQ:GELS) surged 50.64% in after-hours trading following the announcement of positive preclinical results demonstrating a 22% increase in cannabidiol (CBD) bioavailability compared to an FDA-approved oil-based product. The results, attributed to its patented oral gel platform, position the company to enhance competitive advantages in the medicinal cannabis sector. Additionally, plans to leverage Australia’s Special Access Scheme for expedited market entry further bolster growth prospects. The significant price movement aligns with reports from multiple sources, including Benzinga and Spanish-language updates, which highlighted the preclinical data as a catalyst for investor optimism.